| Date Filed | Type | Description |
| 04/12/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 04/09/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/02/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/02/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/02/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/02/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/02/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/02/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 04/02/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 04/02/2019 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 04/02/2019 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 04/02/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 03/28/2019 |
10-K/A
| Annual Report for the period ended December 31, 2018 [amend] |
| 03/26/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 03/20/2019 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Civitas, Entegra, and Immune Design on Behalf of Stockholders and Encourages Investors to Contact the Firm |
| 03/15/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 03/15/2019 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 03/13/2019 |
10-K
| Annual Report for the period ended December 31, 2018 |
| 03/11/2019 |
SC 13G/A
| EcoR1 Capital, LLC reports a 0% stake in Immune Design Corp. |
| 03/05/2019 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 03/05/2019 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 02/28/2019 |
SC 13D/A
| Versant Venture Capital III, L.P. reports a 4.6% stake in IMMUNE DESIGN CORP. |
| 02/25/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/22/2019 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 02/22/2019 |
GN
| Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Immune Design Corp. (IMDZ) on Behalf of Stockholders and Encourages IMDZ Investors to Contact the Firm |
| 02/21/2019 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 02/21/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders |
| 02/21/2019 |
8-K
| Quarterly results |
| 02/21/2019 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 02/21/2019 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 02/19/2019 |
SC 13D/A
| COLUMN GROUP L P reports a 13.8% stake in Immune Design Corp. |
| 02/14/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/28/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|